Surgical Science Sweden AB (SUS)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 58.50 |
|---|---|
| 52-week range | 23.70 – 89.05 |
| Return, 1 month / 3 months | +18.5% / +79.3% |
| Return, 1 year / 3 years | −33.8% / −51.3% |
| Trend | Uptrend |
| RSI (14) | 71 |
| Volatility (1 year) | 105.2% |
| Worst drawdown (1 year) | -73.3% |
| Average daily value traded | 10.68M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Surgical Science Sweden AB makes virtual reality simulators and software for training surgeons and other medical professionals. Its simulator platforms let clinicians practise and assess surgical and clinical skills in a realistic, computer-generated environment. Customers include hospitals, medical schools and training centres that use the equipment for education and skills assessment. The company is based in Gothenburg, Sweden, and develops both the hardware and the software behind its training systems.
The shares are listed on the Nasdaq Stockholm in Sweden under the code SUS, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 3 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Surgical Science Sweden AB (SUS) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 58.50 on 27 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 346 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 33.8% and over the last three months it rose 79.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 58.3% | ||
| From 52-week high | -33.8% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 79.3% | ||
| 6-month return | 75.1% | ||
| 12-month return, skipping the last month | -44.1% | ||
| Stability (higher is calmer) | 15 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 105.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -73.3% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 10.68M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 3 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +6.0% |
|---|---|
| 1 month | +18.5% |
| 3 months | +79.3% |
| 6 months | +75.1% |
| 1 year | −33.8% |
| 3 years | −51.3% |
| 5 years | −76.2% |
Signals
| 50-day / 200-day average | 51.98 / 36.95 |
|---|---|
| Golden / death cross (60 days) | Golden, 42 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.06 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Nov 2023 | SEK 0.3500 |
| 15 Jun 2023 | SEK 0.6000 |
| 16 Feb 2023 | SEK 0.3800 |
| 3 Nov 2022 | SEK 0.3500 |
| 16 Jun 2022 | SEK 0.5700 |
| 17 Feb 2022 | SEK 0.3600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.